<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181245</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-MC3019-028</org_study_id>
    <nct_id>NCT01181245</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives&#xD;
&#xD;
        -  Primary: To evaluate the safety and tolerability of FG-3019 in combination with&#xD;
           gemcitabine and erlotinib&#xD;
&#xD;
        -  Secondary: To evaluate the efficacy and pharmacokinetics of FG-3019 in combination with&#xD;
           gemcitabine and erlotinib&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib</measure>
    <time_frame>Through the end of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FG-3019 PK parameters</measure>
    <time_frame>Through the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Through the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month, 12-month and overall median survival rates</measure>
    <time_frame>Through the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal tumor response as determined by RECIST criteria</measure>
    <time_frame>Through the end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Locally Advanced or Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>FG-3019</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects are treated with FG-3019</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-3019</intervention_name>
    <description>3mg/kg IV, 10mg/kg IV, 15mg/kg IV, 25mg/kg, 35mg/kg IV, 45mg/kg IV - Biweekly, 35/17.5mg/kg, 45/22.5 mg/kg - Weekly</description>
    <arm_group_label>FG-3019</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Written informed consent&#xD;
&#xD;
          2. Males and females aged â‰¥18 years old&#xD;
&#xD;
          3. Histologically or cytologically confirmed adenocarcinoma of the pancreas&#xD;
&#xD;
          4. Locally advanced (Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas&#xD;
&#xD;
          5. Spiral CT scan demonstrating at least one pancreatic adenocarcinoma measurable lesion&#xD;
             according to RECIST criteria and PET scan showing metabolically active lesion (for the&#xD;
             last six subjects in the 15 mg/kg and the subjects in the 25 mg/kg FG-3019 dose&#xD;
             cohorts only)&#xD;
&#xD;
          6. Women of childbearing potential and men must use effective contraception during and&#xD;
             for at least 90 days following study participation. Women of childbearing potential&#xD;
             must have a negative Screening serum pregnancy test.&#xD;
&#xD;
          7. ECOG performance status score of 0-1&#xD;
&#xD;
          8. Life expectancy &gt;12 weeks&#xD;
&#xD;
          9. Ability to adhere to the study visit schedule and understand and comply with all&#xD;
             protocol requirements and instructions from study staff&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Absolute neutrophil count (ANC) &lt;500 cells/mm3&#xD;
&#xD;
          2. Hemoglobin &lt;10.0 g/dL&#xD;
&#xD;
          3. Platelet count &lt;100,000 cells/mm3&#xD;
&#xD;
          4. Bilirubin &gt;2.0 x upper limit of normal (ULN)&#xD;
&#xD;
          5. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &gt;2.5 x ULN, or&#xD;
             &gt;3.5 x ULN if liver metastases are present&#xD;
&#xD;
          6. If the subject is diabetic, HbA1c &gt;10%&#xD;
&#xD;
          7. Current pregnancy or breast feeding due to recent pregnancy&#xD;
&#xD;
          8. History of another malignancy in the past 2 years with the exception of basal cell or&#xD;
             squamous cell carcinoma of the skin&#xD;
&#xD;
          9. Previous chemotherapy with gemcitabine&#xD;
&#xD;
         10. Previous systemic antineoplastic agent (other than adjuvant 5-fluorouracil as&#xD;
             radio-sensitizer)&#xD;
&#xD;
         11. Adjuvant 5-fluorouracil within 28 days prior to Day 1&#xD;
&#xD;
         12. Major surgery within 28 days prior to Day 1 (stent placement is allowed)&#xD;
&#xD;
         13. Radiation therapy within 28 days prior to Day 1&#xD;
&#xD;
         14. Clinical evidence or any history of brain metastasis&#xD;
&#xD;
         15. Uncontrolled hypertension (systolic blood pressure [SBP] &gt;180 mmHg or diastolic blood&#xD;
             pressure [DBP] &gt;105 mmHg)&#xD;
&#xD;
         16. New York Heart Association Class III or IV congestive heart failure&#xD;
&#xD;
         17. History of allergic or anaphylactic reaction to human, humanized, or chimeric&#xD;
             monoclonal antibodies&#xD;
&#xD;
         18. Current clinical or laboratory evidence of active infection requiring antibiotic or&#xD;
             antiviral therapy&#xD;
&#xD;
         19. Active major gastrointestinal bleeding&#xD;
&#xD;
         20. Full-dose heparin therapy within 28 days prior to Day 1&#xD;
&#xD;
         21. Participation in studies of investigational products within 42 days prior to Day 1&#xD;
&#xD;
         22. Clinically significant and uncontrolled medical condition considered a high risk for&#xD;
             participation in an investigational study or a likelihood that the subject will be&#xD;
             unable to comply with protocol requirements and complete the trial (e.g., emphysema&#xD;
             requiring supplemental oxygen, poorly controlled arrhythmia, psychiatric illness,&#xD;
             Alzheimer's disease)&#xD;
&#xD;
         23. Current abuse of alcohol or drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert C Koong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Marc Pipas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincent J Picozzi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Mason Hospital/Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter J O'Dwyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Smitha Krishnamurthi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals of Cleveland, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Lopez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathan Bahary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University (OHSU)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

